RMC No. 27-2026: Updated FDA List of VAT-Exempt Drugs for Cancer, Diabetes, Hypertension, and Other Illnesses

RMC No. 27-2026 updates the FDA-endorsed VAT-exempt drug list for cancer, diabetes, hypertension, kidney disease, mental illness, and more. Businesses selling covered medicines must immediately check whether their pharmacy, hospital, distribution, accounting, and point-of-sale systems reflect the updated VAT-exempt drug list endorsed by the Food and Drug Administration. RMC No. 27-2026 publishes the updated full […]

RMC No. 108-2025: Updated VAT-Exempt Drug List for Cancer, Diabetes, Hypertension, Kidney Disease, Mental Illness, Tuberculosis, and High Cholesterol

RMC No. 108-2025 updates the FDA-endorsed VAT-exempt drug list for key illnesses, affecting pharmacies, healthcare firms, and corporate tax teams. Businesses selling, importing, prescribing, purchasing, reimbursing, or accounting for qualified medicines must immediately validate their product master files, invoices, VAT treatment, and reimbursement rules against the updated VAT-exempt drug list endorsed by the Food and […]

RMC No. 122-2020: VAT-Exempt Drugs List Clarified by FDA Based on Generic Names and Salt Forms

RMC No. 122-2020 clarifies VAT-exempt drug treatment using FDA-listed generic names or INNs, including salt forms, for medicine sellers and buyers. Businesses selling, importing, purchasing, or accounting for medicines covered by the VAT-exempt drug rules must review whether their products fall within the clarified FDA list, because the exemption is determined by the International Non-Proprietary […]

RMC No. 4-2019: VAT Exemption for FDA-Listed Diabetes, High-Cholesterol, and Hypertension Drugs

RMC No. 4-2019 publishes the FDA list of VAT-exempt diabetes, high-cholesterol, and hypertension drugs for pharmacy and healthcare VAT compliance. Pharmacies, hospitals, drug distributors, and VAT-registered sellers of medicine must treat the FDA-identified drugs for diabetes, high cholesterol, and hypertension as VAT-exempt once covered by the published FDA list. RMC No. 4-2019 matters because the […]